MiNK Therapeutics, Inc.
INKT
NASDAQ·Healthcare·Biotechnology·Mkt cap $58.0M
$11.64
▲ +3.65%
P/E
-4.87
Mkt Cap
$58.0M
52-Wk Range
$8.48–$16.98
52-Week Range
$8.48 - $16.98
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 26.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Off-the-shelf allogeneic cell therapy eliminating personalization costs
- Proprietary invariant natural killer T cell platform technology
- Backing and resources from parent company Agenus Inc.
- First-mover advantage in iNKT cell therapy commercialization
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Stable outlook
Advancement of AGENT-797 through Phase 1 and subsequent clinical trials
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+2.6% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying INKT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 13, 2026
Reported EPS of -$0.62 vs -$0.60 consensus (-3.3% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-3.3%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · May 18, 2026
vs Industry
How INKT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related